Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-73

Agreed. The market knows best. And at the moment it hates risk.

A lot of the selling into the 4c zone has been holders with an average of somewhere between 12c and 35c selling to rebuy at 2.8c. This has created the sell pressure. But, with several days of higher than normal volume, they have been finding buyers. So we have a new base in the 3cish zone.

That sell pressure will dry up today, as T+2 and bpay wait makes today the last day to take advantage of the 2.8c buy back.

If volume return to its very low historical value, the price will drift up and down on small sell and buy orders. But if we get the right announcement to keep interest, it will drift up. But very hard to predict when volume historically is so low.

For me, I have taken a large position which will be averaged in the low 3c region now, and will hold until we hear more from the expansion trial into GBM.

Risks at the moment are that this raise fails in a large way. Or that the drugs dont keep performing as they should.

Mitigation for the finds if the raise fails, is delaying the new trial from hitting arms. Not ideal, but concentration of funds into GBM approval would be best for the company.
Data so far seems to point to the drugs working a treat.

So a rocky path ahead, but potential from this market cap is large.